58349-96-5

Usage

Uses

Used in Biochemical Research:
5-Bromo-2-hydroxybenzylamine is utilized as a key intermediate in biochemical research for its ability to participate in various chemical reactions due to its reactive functional groups, thus facilitating the development of new biochemical compounds and understanding of molecular interactions.
Used in Pharmaceutical Research and Drug Synthesis:
In the pharmaceutical industry, 5-Bromo-2-hydroxybenzylamine serves as a crucial building block in the synthesis of diverse drugs and biochemicals. Its chemical reactivity allows for the creation of a broad spectrum of medicinally relevant compounds, contributing to the advancement of treatments for various diseases and conditions.

InChI:InChI=1/C7H8BrNO/c8-6-1-2-7(10)5(3-6)4-9/h1-3,10H,4,9H2

Upstream product

• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 6329-74-4 5-bromo-2-hydroxybenzamide 

Downstream Products

• 1199-04-8 6-bromo-3,4-dihydro-benzo[e][1,3]oxazin-2-one 
• 903557-06-2 benzyl (5-bromo-2-hydroxybenzyl)carbamate 
• 370577-54-1 Fe₂(BrC₆H₃OCH₂NCHC₆H₄O)2((C₆H₅O)2PO₂)2 
• 370577-52-9 Fe₂(BrC₆H₃OCH₂NCHC₆H₄O)2(C₆H₅CO₂)2 

Relevant academic research and scientific papers

Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens

A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

IN VIVO IMAGING COMPOUNDS

The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor. [image]

COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS

The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1, 4, 5- trisphosphate 3 -kinase B (ITPKb).

SUBSTITUTED PYRIMIDINES

The invention relates to novel substituted pyrimidines of formula (I), in which R1, R2, R3, R4, Q, X and n have the meanings as cited in the description. The invention also relates to a method and intermediate products for producing these pyrimidines, and to the use thereof as plant control agents, particularly as herbicides.